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Abstract
Background: The disease burden of human immunodeficiency virus (HIV) - acquired immunodeficiency syndrome 
(AIDS) is highest in sub-Saharan Africa but there are few studies on the associated neurocognitive disorders in this 
region. The objectives of this study were to determine whether Western neuropsychological (NP) methods are 
appropriate for use in Cameroon, and to evaluate cognitive function in a sample of HIV-infected adults.
Methods: We used a battery of 19 NP measures in a cross-sectional study with 44 HIV+ adults and 44 demographically 
matched HIV- controls, to explore the validity of these NP measures in Cameroon, and evaluate the effect of viral 
infection on seven cognitive ability domains.
Results: In this pilot study, the global mean z-score on the NP battery showed worse overall cognition in the HIV+ 
individuals. Significantly lower performance was seen in the HIV+ sample on tests of executive function, speed of 
information processing, working memory, and psychomotor speed. HIV+ participants with AIDS performed worse than 
those with less advanced HIV disease.
Conclusions: Similar to findings in Western cohorts, our results in Cameroon suggest that HIV infection, particularly in 
advanced stages, is associated with worse performance on standardized, Western neurocognitive tests. The tests used 
here appear to be promising for studying NeuroAIDS in sub-Saharan Africa.
Background
Neurological complications affecting the central and
peripheral nervous systems are common in HIV infec-
tion. The vast majority of studies on HIV-related neu-
rocognitive disorders were performed in developed
countries, on patients infected with HIV-1 subtype B [for
recent reviews, see [1-4]]. Two-thirds of the estimated
33.2 million individuals currently living with the human
immunodeficiency virus (HIV)/acquired immunodefi-
ciency syndrome (AIDS) worldwide are in sub-Saharan
Africa (SSA) and are infected with mostly non-B HIV
subtypes. Thus, it is important to diagnose and categorize
HIV effects on the central nervous system (CNS) in SSA
[4,5].
Autopsy studies of HIV-infected individuals have
shown that the brain is the second organ most frequently
affected by HIV infection [6]. Studies of neuroAIDS
pathogenesis have established that following HIV infec-
tion, the virus rapidly crosses the blood-brain barrier and
enters the brain, where it productively infects brain mac-
rophages and microglia [for recent reviews, see [3,7-9]].
Toxic HIV proteins and cytokines secreted by infected
mononuclear phagocytes in the brain cause dysfunction
of other CNS cells and neuronal death [10-12]. This HIV-
induced brain pathology often results in behavioral,
motor and cognitive abnormalities referred to as HIV-
associated neurocognitive disorders (HAND) [13]. HIV-
associated dementia (the most severe form of HAND) has
been described as a sub-cortical dementia, yet clinical
and pathological studies have also shown an association
between cortical neurodegeneration and HIV-associated
neurocognitive impairment in infected patients [4,14,15].
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Like many countries in SSA, Cameroon still has a heavy
burden of the HIV/AIDS epidemic. According to recent
estimates, the prevalence of HIV infection in the overall
adult population of Cameroon is 5.1%, with prevalence of
8.3% in large metropolitan areas like the capital city
Yaoundé, 7.4% among women, and 26.4% in female sex
workers [16-18]. Furthermore, Cameroon has a high
genetic diversity of HIV strains including several group
M HIV-1 subtypes, HIV-1 groups O and N, circulating
recombinant forms and unique recombinant forms [19-
23]. Therefore, it is important to understand the neuro-
logical and neurocognitive effects of HIV infection in this
country.
A comprehensive NP battery was recently adapted and
successfully used to produce normative data in healthy
children in Cameroon [24]. Also, we have screened HIV-
infected adults in Yaoundé for HAND and its risk factors
using the International HIV Dementia Scale (IHDS)
[25,26]. Although the IHDS is simple and rapid, it is nei-
ther comprehensive nor able to assess specific cognitive
functional domains. The goal of the current study was to
adapt the HIV Neurobehavioral Research Center (HNRC,
University of California at San Diego) international NP
test battery in Cameroon, and to explore its validity for
the detection of HAND in infected Cameroonians. This
battery included 19 test measures designed to evaluate
several ability domains known to be vulnerable to HIV
effects on the brain, including abstraction/executive
function, speed of information processing, attention and
working memory, verbal fluency, motor ability, learning
and delayed recall [27-29]. This preliminary report
describes the first attempt to examine the effect of HIV
infection on specific cognitive domain functions in
infected individuals in Cameroon.
Methods
Setting and study design
This study is part of an ongoing project funded by the
United States National Institute of Mental Health aimed
at studying the neurological complications of HIV infec-
tion in Cameroon. The study was approved by the Cam-
eroon National Ethics Committee, as well as the
Institutional Review Board of the University of Nebraska
Medical Center, and the Cameroon Ministry of Public
Health delivered the administrative authorization for this
research. This was a cross-sectional study comparing
HIV-seropositive (HIV+) cases and HIV-seronegative
(HIV-) controls. The HIV+ subjects were further classi-
fied as AIDS and non-AIDS based on clinical and immu-
nological criteria: Center for Disease Control (CDC)
clinical disease stage and CD4 T-lymphocyte counts
[30,31]. All clinical and neuropsychological testing was
performed in the Neurology Department of the Yaoundé
Central Hospital, Yaoundé, Cameroon.
Training and adaptation of the neuropsychological battery
For this study, we used the HNRC international NP test
battery, a battery that has been shown to be sensitive in
detecting HAND in the USA, India, and China [27-
29,32]. This battery (Table 1) was administered by psy-
chologists trained in psychometrics. To adapt NP and
neuromedical procedures to Cameroon settings and
ensure standardization, the Cameroon investigators
(GDK, AKN, and CK) were trained and certified by
American neuropsychologists and psychometrists (RKH,
LAC, DRF) at the HNRC, University of California San
Diego, U.S. The Cameroon investigators trained at HNRC
then trained other Cameroonian examiners (psycholo-
gists, RD, SE) in Yaoundé, Cameroon who were certified
by HNRC following review of their video-recorded test-
ing sessions using staff volunteers from the Neurology
Department, Yaoundé Central Hospital, Cameroon. We
translated all tests in the battery and test instructions into
French. For the Hopkins Verbal Learning Test-Revised
(HVLT-R), we used the version previously translated into
French and validated by Rieu and colleagues [33]. The
French version of the HNRC NP battery was tested,
piloted, and approved by all bilingual (French- and Eng-
lish-speaking) scientists on the team (GDK, CTK, AKN,
LAC). Selected NP tests were back-translated into Eng-
lish and back-translated tests were similar to the original
English version of the tests. At the beginning of the study
in Cameroon, quality assurance reviews were conducted
by HNRC scientists on test forms of the first 5 visits, and
thereafter on randomly selected 5 to 10% of all visits.
Neuropsychological tests
Table 1 show the tests used in this study for a comprehen-
sive neuropsychological assessment of subjects, grouped
by ability domain:
Verbal fluency tests included tests of verbal, animal and
action fluency, which measure the ability of generating
words beginning with a given letter [34,35] or by category
[36,37].
Executive functions tests included the Halstead Cate-
gory Test [38], Wisconsin Card Sorting Test-64 (WCST-
64) [39], and Colors Trails II [40]. The WCST-64 is a
measure of frontal lobe function that assesses the ability
to learn concepts, perseverance and competence in
abstract reasoning. The Category test is also a measure of
frontal lobe function and includes 7 subtests: subtests I
and II evaluate number counting and attention; subtests
III and VI measure visual abstract reasoning and memory
respectively; subtests IV and V measure visual perception
and spatial orientation respectively, while subtest VII
evaluates learning and retention of the concepts associ-
ated with other subtests [38].
Speed of information processing tests: the Wechsler
Adult Intelligence Scale (WAIS)-III Digit Symbol andKanmogne et al. BMC Neurology 2010, 10:60
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WAIS-III Symbol Search tests [41] produces measures of
processing speed, visual perception, attention, concentra-
tion, visual-motor coordination, motor and mental speed.
The Stroop Color and Word tests [42] measures cognitive
processing and can provide valuable diagnostic informa-
tion on brain dysfunction, cognition, mental speed and
mental control. The Color Trails and Trail Making Test
produces measures of attention, visual searching, mental
processing speed, and measure the ability to mentally
control simultaneous stimulus pattern [40].
Memory learning and memory recall tests: the Brief
Visuospatial Memory Test-Revised (BVMT-R) [43] mea-
sures visual learning and memory while the HVLT-R [44]
assesses verbal learning and memory. Both BVMT-R and
HVLT-R also assess recognition and recall.
Working memory tests: the Paced Auditory Serial Addi-
tion Test (PASAT)-50 is a measure of cognitive function
that specifically assesses the processing speed of auditory
information, concentration, flexibility, mental calcula-
tion and mental tracking abilities [45,46]. The Wechsler
Memory Scale (WMS) Spatial Span provides an estimate
of general memory functioning and is sensitive to mem-
ory impairments associated with various clinical condi-
tions [47].
Motor function test: the Grooved Pegboard test (domi-
nant and non-dominant hand) measures performance
Table 1: Neuropsychological (NP) tests battery and Z-scores (mean ± SD) in the HIV+ group
Ability domain NP tests (reference) HIV+ (N = 44) P < d
Verbal Letter Fluency [34,35] -0.07 ± 1.02 0.72 .07
Animal Fluency [35] -0.17 ± 0.82 0.37 .18
Action Fluency [36,37] -0.15 ± 0.70 0.42 .17
Executive Functions Category Test [38] -0.53 ± 0.95 0.01 .52
WCST-64 Total Errors [39] -0.88 ± 1.40 0.002 .68
Color Trails II [40] -0.34 ± 1.07 0.34 .31
Speed of information processing TMT-A (U.S. War Department, 1944) -0.04 ± 0.84 0.83 .04
WAIS-III Digit symbol [41] -0.33 ± 0.86 0.09 .34
WAIS-III Symbol Search [41] -0.33 ± 0.83 0.10 .34
Stroop Color [42] -0.30 ± 0.97 0.15 .29
Color Trails I [40] -0.17 ± 0.95 0.41 .17
Memory Learning BVMT-R Learning [43] -0.33 ± 1.14 0.15 .29
HVLT-R Learning [44] -0.08 ± 1.20 0.71 .07
Memory Recall BVMT-R Delay Recall [43] -0.42 ± 1.30 0.09 .35
HVLT-R Delay Recall [44] -0.18 ± 1.05 0.41 .17
Working Memory PASAT 50 [45,46] -0.49 ± 0.96 0.02 .48
WMS-III Spatial Span [47] -0.41 ± 0.89 0.04 .41
Motor function Grooved Pegboard DH [48] -0.18 ± 1.17 0.42 .16
Grooved Pegboard NDH [48] -0.26 ± 1.23 0.28 .22
Mean Z-score -0.30 ± 0.64 0.05 .41
Raw scores were transformed into z-scores using the control's mean and standard deviation. P represents statistical significance when 
comparing mean z-scores or HIV+ and mean z-scores of HIV- group. Abbreviations: SD: standard deviation; WCST: Wisconsin Card Sorting 
Test; TMT-A: Trail Making Test part A; WAIS: Wechsler Adult Intelligence Scale; BVMT-R: Brief Visuospatial Memory Test-Revised; HVLT-R: 
Hopkins Verbal Learning Test-Revised; PASAT: Paced Auditory Serial Addition Test; WMS: Wechsler Memory Scale; DH: dominant hand; NDH: 
non-dominant hand.Kanmogne et al. BMC Neurology 2010, 10:60
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speed and requires complex visual-motor coordination
[48].
Participants and data collection
HIV+ individuals and seronegative controls were
recruited from January 2008 to June 2009 at 1) the HIV
voluntary counseling and testing sections of the Daycare
Hospital in the Yaoundé Central Hospital; and 2) the
Health and Social Welfare Centre of the University of
Yaoundé I. The purpose of the study and research proce-
dures were fully explained to participants and adults 18 to
60 years old who gave a written consent were allowed to
participate in the study. The exclusion criteria were: 1)
present or past history of CNS disease unrelated to HIV,
2) head trauma, 3) current alcohol intoxication (blood
alcohol content of each participant was measured using a
Breathalyzer), 4) known psychiatric disease or treatment
with antipsychotic drugs, and 5) ongoing systemic illness
or fever with temperature of 37.5°C or higher. All subjects
enrolled spoke French as their primary language and
interviews were conducted in French. All participants
provided demographic information, underwent a thor-
ough neurological assessment and a complete medical
history and physical examination by neurologists at
Yaoundé Central Hospital, before NP testing, to detect
any focal neurological deficit suggestive of CNS opportu-
nistic infection. This thorough clinical assessment of each
subject combined with review of his or her prior medical
history and laboratory data, ensured that potential con-
founding factors such as CNS opportunistic infections
were ruled out.
Beck Depression Inventory [49] and NP tests were
administered to each subject by trained psychologists/
psychometrists in the Neuropsychology Room of the
Neurology Department: a private, quiet and well-lit
room. Following neurological and general medical assess-
ment and NP testing, blood samples were collected for
serology. The HIV status of each participant was deter-
mined using the rapid immunochromatographic HIV-1/2
test (Abbott Diagnostics, Chicago, IL, USA) and the
Murex HIV antigen/antibody Combination ELISA
(Abbott Diagnostics). A participant was considered HIV+
if they tested positive for the 2 tests and HIV- if negative
for both tests, and discordant if positive for only one test.
No discordant result was observed in this study. The CD4
T-lymphocyte count of infected individuals was deter-
mined by flow cytometry, using a Fluorescence Activated
Cell Sorting (FACS) Count Instrumentation System (BD
Biosciences, San Jose, CA, USA). For viral load quantifi-
cation we used the Abbott Real-Time Viral Load Test,
with Abbott m2000 system (Abbott Diagnostics). All bio-
logical tests were done in the Haematology Laboratory of
the University Hospital Center, Yaoundé, Cameroon.
Data analysis
Eighty-eight (88) individuals, of whom 44 were HIV+ and
44 HIV- completed the NP battery. Both groups were well
matched for age, education, and gender (Table 2). Raw
scores were transformed into z-scores using the control
group's mean and standard deviation. All z-scores were
coded so that increasingly negative scores indicated
worse performance. The t-test was used to statistically
compare the HIV+ and HIV- groups on each of the 19 NP
measures, and Cohen's d effect sizes were also computed.
A summary score on the NP battery was obtained by
averaging the 19 individual z-scores to reflect overall level
of NP performance, and scores on measures in each of
the seven ability domains were averaged to create domain
summary scores. We also explored the magnitude of
demographic effects on test performance in our Camer-
oon participants, which would need to be controlled in a
norms development project before the tests could be
used confidently to classify cognitive impairment in indi-
vidual Cameroonians. Thus, the individual effects of age,
education and gender were tested using standard regres-
sion analyses, separately in the HIV- and HIV+ groups,
and for each cognitive ability domain. All effect sizes were
corrected for small samples size bias using Hedges' cor-
rection. The seronegative control group, the non-AIDS
and AIDS subgroups were compared using analysis of
variance (ANOVA) and post hoc Dunnett's comparisons
on the overall mean z-score and mean z-scores on the
seven ability domains. Secondary analyses included as
covariates those demographic variables that were signifi-
cant in univariate analyses. Analyses were conducted
using the JMP statistical software version 7.0 (SAS Inc;
2008).
Results
Demographic, clinical and laboratory characteristics
A total of 88 (44 HIV+ and 44 HIV-) adult Cameroonians
were evaluated. Participants' demographic, clinical and
laboratory characteristics are summarized in Table 2. All
participants were screened for sub-optimal effort using
the Hiscock forced-choice recognition test cut-off of less
than 90%. Only one individual in the control group
scored in the sub-optimal effort range and was excluded
from further analyses. There was no statistically signifi-
cant difference between cases and controls in age, educa-
tion, or sex (% female) (Table 2). Of the 44 HIV+
individuals, 22 (50%) were classified as non-AIDS and 22
as having AIDS (Table 3): CD4 T-lymphocytes counts
below 200 cells/μl and AIDS indicator conditions as spec-
ified in the CDC AIDS case definition criteria [30,31]. Fif-
teen of the 44 HIV+ individuals (34%) were on
antiretroviral therapy (ART) and as expected their viral
load was significantly lower than that of AIDS and non-
AIDS HIV+ individuals who were not on ART (Table 3).Kanmogne et al. BMC Neurology 2010, 10:60
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NP tests performance of controls and HIV-infected patients 
in Cameroon
Table 1 contains the z-scores of the HIV+ and HIV-
groups for all 19 test instruments used in this study. The
summary mean z-scores across all 19 test measures
showed that HIV+ group performed significantly less
well in NP testing than HIV- controls (P < 0.05). Compar-
isons of individual z-scores for each of the 19 test mea-
sures showed that for the WCST-64, PASAT-50, Category
test, and Spatial Span, the NP performance of HIV+ indi-
viduals was significantly lower than that of HIV- controls.
Computation of effect sizes further showed that effect
sizes were medium for the Category Test and WCST-64
(both measures of executive function), and small-to-
medium for PASAT-50 and Spatial Span (measures of
working memory), although not statistically significant
with the current sample sizes. Small-to-medium HIV sta-
tus effects sizes were also noted on another measure of
executive function (Color Trails-II), as well as on mea-
sures of speed of information processing (Digit Symbol,
Symbol Search) and visual episodic memory (BVMT-R).
Finally, small effect sizes for HIV status were also seen for
another measure of processing speed (Stroop Color
Naming) and a measure of motor function (Grooved Peg-
board, Non-dominant Hand). Although mean scores on
all tests in the battery were worse for the HIV+ group
than the HIV- group, only a minimal effect (d < 0.2) was
observed on the remaining eight measures in Table 1
(especially on tests of verbal fluency and verbal episodic
memory).
As expected, very substantial demographic effects were
present in the data and influenced NP performance. Age
and education independently and in combination pre-
dicted global mean z-scores and ability domain mean z-
scores in both HIV- and HIV+ groups, with demographic
effects more pronounced in the control group (Table 4).
Older age and lower education were associated with
lower NP performance; gender had no effect on NP per-
formance, except for verbal tests where gender signifi-
cantly influenced mean z-scores in the control group
(Table 4).
NP tests performance of AIDS patients and non-AIDS HIV+ 
individuals
The AIDS subgroup of HIV+ volunteers performed sig-
nificantly worse on the NP tests than either the HIV- con-
trols (P = 0.005) or the non-AIDS HIV+ subgroup (P <
0.01). Compared to the mean z-score for the overall per-
formance of HIV- controls (-0.01 ± 0.7), the mean z-score
for the overall performance of the AIDS subgroup was -
0.54 ± 0.63 (P = 0.005), while mean z-score of non-AIDS
HIV+ subgroup was -0.05 ± 0.56. Adjusting performance
for age and education yielded comparable results. The
AIDS and non-AIDS HIV+ subgroups had the same
demographic characteristics and when NP performance
was adjusted for age and education, AIDS patients still
performed worse than non-AIDS and controls. Analysis
of mean ability z-scores of controls, AIDS, and non-AIDS
for each of the 7 ability domains showed that AIDS
patients performed significantly worse (P < 0.01) than
controls in NP tests assessing executive function, speed
of information processing, memory recall, and working
memory (Figure 1). Analyses adjusting for demographic
effects (age, education, gender) gave similar results. Com-
pared to controls, individuals in the AIDS group also had
lower mean z-scores on tests assessing verbal, memory
learning, and motor functions, but the difference was not
statistically significant. Similarly, NP performance of
Table 2: Demographic and clinical characteristics of the HIV+ and HIV- groups
HIV- HIV+ P value
(N = 43) (N = 44)
Age 33.26 ± 11.40 34.91 ± 10.25 .48
Education 12.60 ± 4.44 12.11 ± 3.9 .58
Speak French 100% 100%
Sex (% female) 58.1% 61.4% .76
AIDS % - 50%
BDI-II 14.64 ± 9.48 13.48 ± 8.88 .56
BDI-II: Beck depression inventory 2nd edition [49].Kanmogne et al. BMC Neurology 2010, 10:60
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HIV- and non-AIDS HIV+ groups showed no significant
difference in all 7 ability domains tested (Figure 1).
Computation of effect sizes when comparing the HIV-
controls versus the AIDS subgroup, and HIV- versus the
non-AIDS HIV+ subgroup, showed medium-to-large
effect sizes for overall cognitive and executive function
and working memory (Table 5). Effect sizes were medium
for speed of information processing and memory recall,
and small-to-medium for verbal fluency, learning, and
motor function (Table 5). Global and ability domain
mean z-score effect sizes showed no difference between
the overall performance of non-AIDS HIV+ subgroup
and HIV- controls (Tables 5), however a small effect of
non-AIDS HIV infection was observed for executive
function.
Discussion
This is the first study of NP performance and impairment
of specific cognitive domains using a comprehensive and
validated NP assessment battery in HIV-infected individ-
uals in Cameroon. After translation into French and
when administered by trained examiners, this battery
detected cognitive dysfunction in HIV-infected Camer-
oonians. Participants were able to understand, follow test
instructions, and validly complete NP tests, including
computerized tests such as the Category test, WCST-64,
and PASAT-50. All HIV- and HIV+ subjects were
recruited in the same settings/hospitals in Yaoundé,
Cameroon, and shared similar demographic features. As
in many SSA countries, it has been shown that HIV trans-
mission in Cameroon is predominantly (> 90%) through
unprotected heterosexual contact [50] which reduces the
likelihood of comorbid conditions that may affect the
CNS (e.g., substance use disorders, co-infection with
Hepatitis-C due to injection drug use that is a common
risk for HIV infection in other parts of the world). Cul-
tural differences probably affect performances on NP
tests in a similar way as education differences. However
this will not necessarily affect the validity of the NP tests
for measuring disease related CNS dysfunction because
the basic abilities assessed (verbal fluency, learning,
attention and working memory, cognitive processing
speed, executive function) exist and have some relevance
in any population. Moreover, these cultural differences
are mitigated when controls and diseased groups are
from the same population with similar culture, as in this
study.
HIV infection in Cameroon appears to be associated
with impairment of cognitive function in domains similar
to those most affected by HIV in geographic regions out-
Table 3: Laboratory characteristics of the HIV+ group
Mean CD4 ± SE P Mean viral load ± SE P
(Cells/μl) [IQR] (Log copies/ml) [IQR]
HIV+ Non-AIDS (N = 22) 496 ± 51.5 2.86 ± 0.47
[597.5 - 323] [4.7 - 0.65]
0.0005 0.1
HIV+AIDS (N = 22) 251 ± 38.9 4 ± 0.5
[360.5 - 117] [5.88 - 1.85]
HIV+ Non-AIDS 493.4 ± 70.5 3.95 ± 0.38 0.0001
No ART (N = 16) [620 - 268] [5 - 2.78]
NS
HIV+ Non-AIDS 502.8 ± 47.6 0.33 ± 0.3
ART (N = 6) [620.5 - 375] [0.98 - 0.0]
HIV+AIDS 225.5 ± 42 5.12 ± 0.46
No ART (N = 13) 332.5 - 128] NS [6.1 - 4.84] 0.0014
HIV+AIDS 292.5 ± 77.5 2.15 ± 0.67
ART (N = 9) [471.5 - 109] [3.65 - 0.65]
SE: standard error; IQR: interquartile range; ART: Antiretroviral therapy; N: sample size; NS: not significant.Kanmogne et al. BMC Neurology 2010, 10:60
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side West Africa. Specifically, AIDS patients performed
worse than non-AIDS HIV+ and HIV- groups on the
global NP testing and NP tests assessing executive func-
tion, speed of information processing, working memory,
and memory recall. In general, compared to HIV- con-
trol, the pattern of cognitive deficits was similar in non-
AIDS HIV+ and AIDS groups, with deficits more pro-
nounced in AIDS patients for all cognitive domains. Our
results also indicate that neurocognitive impairment
increases as the disease progress and is strongly associ-
ated with advanced immune deficiency and clinical dis-
ease, consistent with findings in the developed world.
Effects from opportunistic infections are unlikely to have
caused NP impairment because persons with a history of
these diseases were excluded. All study participants were
recruited at Yaoundé hospital out-patient clinics,
appeared physically well and came to the clinics alone,
without any support from a caregiver; thus, it is unlikely
that patients in the AIDS group performed poorly
because they were feeling too sick to perform at their
best.
Other studies have shown increased rates of neurocog-
nitive impairment with advanced stages of HIV infection
[51-53]. Using this comprehensive NP battery, Heaton
and colleagues [28,29] showed that HAND is an impor-
tant feature of HIV infection in China, and the impair-
ment pattern, severity, and prevalence were similar to
those reported in Western countries. Studies in India
showed deficits in the domains of fluency, working mem-
ory, memory and learning in Clade C HIV-infected indi-
viduals, with AIDS patients showing greater impairment
in visual working memory than non-AIDS and seronega-
tive controls [32]. Robertson and colleagues [54] evalu-
ated NP performance among HIV+ individuals in Uganda
and found that compared to HIV- controls, the HIV+
group showed significant deficits on measures of learning
Table 4: Individual (Pearson r) effects of age, education and sex on global (mean z-score) and ability domains (mean 
ability z-score) neuropsychological performance
HIV- HIV+
Age Education Sex Age Education Sex
Mean Z-score -.57 ***;.72****; -.01 -.38 **;.55***; .14
Verbal -.41 **; .53**; -.38* -.005;.47**; .10
Executive function -.50 ***;.55***; -.18 -.22;.38*; .00
Speed information processing -.52 ***;.72****; -.03 -.33*;.47**; .08
Memory Learning -.42 ***;.49****; -.11 -.43 **;.48***; .17
Memory Recall -.41 ***;.46***; -.10 -.51 ***;.56***; .16
Working Memory -.49 ***;.65****; -.19 -.11;.10; .09
Motor function -.50 ***;.55***; .20 -.38 *;.42**; .16
*P < 0.05; **P < 0.005; ***P < 0.001; **** P < 0.0001. Age and education influenced neuropsychological performance, and this was more 
pronounced in the control group. Gender did not have a significant effect on neuropsychological performance.
Figure 1 Increased cognitive impairment in AIDS patients com-
pared to non-AIDS and HIV-controls. Mean (± standard error) ability 
z-scores for each group was computed for the seven ability domains, 
analyzed using ANOVA and post hoc Dunnett's comparison. Com-
pared to controls and HIV+ non-AIDS individuals, z-scores of AIDS pa-
tients were significantly lower on Executive function, Speed of 
Information Processing, Memory Recall and Working memory (p < 
0.01).Kanmogne et al. BMC Neurology 2010, 10:60
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and memory, speed of information processing, attention
and executive function.
Clifford and colleagues [55] examined a group of work-
ers in Ethiopia and found that HIV+ patients had slowed
finger-tapping speed, but that the HIV+ and HIV- groups
performed similarly in timed gait, Grooved Pegboard,
and verbal fluency tests. Similarly, we found that perfor-
mance of HIV- and HIV+ groups on the Grooved Peg-
board, and on tests of verbal fluency, and on Trail
making-A or Color Trails-I and II did not differ signifi-
cantly (Table 1). In contrast, our more comprehensive NP
battery found that HIV+ persons (mainly those with
advanced disease) performed significantly worse than
HIV- controls on tests of working memory (PASAT and
WMS-III Spatial Span) and higher level executive func-
tions (Category Test and WCST-64), with smaller (non
significant with the current sample sizes) effect sizes in
the same direction on tests of speed of information pro-
cessing (WAIS-III Digit Symbol and Symbol Search, and
Stroop Color Naming speed) and visual episodic memory
(BVMT-R). Interestingly, in contrast to the latter result
with visual episodic memory and findings in developed
countries, our measures of verbal episodic memory
(HVLT-R learning and recall) did not even show a small
HIV effect. A smaller HIV effect for our verbal than
visual episodic memory measures also was seen in rural
China [29] and may suggest that the visual measures are
more generalizable across cultures.
Several studies had demonstrated that demographic
effects such as age, education, cultural and ethnic differ-
ences affect NP test performance [56-59]. A study of NP
impairment among HIV+ individuals in South Africa
showed that older age, lower education level, post-trau-
matic stress disorder, and alcohol use affected NP perfor-
mance [60]. As expected, demographic effects were also
present in our data as computation of Pearson's r showed
that age and education significantly influenced NP per-
formance, especially in the HIV- group, while gender had
no major effect.
The cognitive impairments observed among HIV+/
AIDS Cameroonians are likely due to HIV infection
because our comparison groups were well matched for
demographic factors and those with confounding condi-
tions such as alcohol intoxication, systemic illness, CNS
or psychiatric diseases were excluded. There are currently
no normative adult NP test data for Cameroon or SSA,
and large demographic effects noted in this study under-
score need for more comprehensive local normative NP
data to improve neurocognitive diagnosis [61]. Our sub-
sequent studies will enroll more HIV- control subjects in
order to establish normative data for NP testing in adult
Cameroonians.
Our pilot study has a number of limitations including:
1) the small sample size which likely limits the power to
detect differences in some individual NP test measures,
precludes us from creating demographically adjusted test
Table 5: Effect sizes between controls, Non-AIDS and AIDS for cognitive domains ability scores and global score
Non-AIDS AIDS AIDS
Ability domain Vs. Vs. Vs.
Controls Controls Non-AIDS
Mean Z-score 0.06 0.74 0.78
Verbal -0.04 0.34 0.44
Executive function 0.28 1.03 0.74
Speed information processing 0.02 0.57 0.71
Memory Learning -0.03 0.46 0.47
Memory Recall 0.02 0.60 0.57
Working Memory 0.13 0.84 0.77
Motor function -0.01 0.40 0.39
All effect sizes were corrected for small sample size bias using Hedges' correction.Kanmogne et al. BMC Neurology 2010, 10:60
http://www.biomedcentral.com/1471-2377/10/60
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scores and from exploring possible effects of ART on cog-
nitive performance; 2) the inability of the current study to
estimate the population prevalence of cognitive impair-
ment due to lack of local normative NP data; 3) lack of
brain imaging and cerebrospinal fluid (CSF) data, due to
limited resources and logistic difficulties, precludes us
from exploring the relationship between HIV-induced
neurologic abnormalities, HIV brain infection (CSF viral
load) and cognitive performance; 4) this study was con-
ducted in an urban setting and findings cannot be gener-
alized to rural settings where inhabitants have much
lower education levels.
A recent United Nations Programme on HIV and AIDS
(UNAIDS) report estimates that over half million Camer-
oonians are currently living with HIV, of which only
about 25% have access to antiretroviral drugs and ART
coverage for prevention of mother-to-child transmission
is less than 25% [17]. In our current study, only 15 of the
44 HIV+ individuals (34%) were on ART, including 6 of
the 22 non-AIDS HIV+ and 9 of the 22 AIDS patients. In
subsequent studies with larger sample size, we will evalu-
ate the effect of ART on neurocognitive performance.
Neurocognitive impairment predicts the presence of HIV
encephalitis [62-64] and is an independent risk factor for
death [65]. In resource limited countries like Cameroon,
many HIV-infected individuals have no access to ART,
and low CD4 cell counts and clinical symptoms remain
the major criteria for selecting patients for ART treat-
ment. Detection of neurocognitive impairment could tar-
get patients for ART, possibly reversing brain dysfunction
in some cases, improving their productivity and quality of
life, and perhaps even prolonging their survival.
Conclusions
Advanced immunosuppression from HIV infection is
a s s o c i a t e d  w i t h  H A N D  i n  C a m e r o o n .  A I D S  p a t i e n t s
showed impairment in executive function, speed of infor-
mation processing, working memory, and memory recall
and the pattern of deficits is similar to that found in many
other areas of the world. Further longitudinal research
with large HIV-infected population is needed to deter-
mine whether suppression of HIV replication through
ART will reduce the prevalence of neurocognitive impair-
ment in Cameroon as observed elsewhere.
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